Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Inc Share Price USD0.0001
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations - Simply Wall St News
Puma Biotechnology 獲Alisertib 授權，與武田共創雙贏! | GeneOnline News
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022
Puma Biotechnology settles with Novartis' Sandoz unit over Nerlynx patent dispute (PBYI) | Seeking Alpha
Here's Why Puma Biotechnology Fell 17.2% in April | The Motley Fool
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Inc (NASDAQ:PBYI) Share Price | RNS News, Quotes, & Charts | PBYI
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
Puma Biotechnology falls more than 20%
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
